Type: Oral
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness
Hematology Disease Topics & Pathways:
Research, Fundamental Science, hematopoiesis, metabolism, Biological Processes, molecular biology
To investigate the relationship between B4galt-dependent glycosylation and HSC function, we analyzed the glycan composition in control and B4galt1 null (B4-/-) femurs by spatial mass spectrometry using matrix-assisted laser desorption ionization-mass spectrometry imaging (MALDI-MSI). In control femurs, we observed a distinct gradient of complex N-glycans, with higher expression at the distal ends and decreasing complexity towards the shaft, showcasing diverse glycan expression in the hematopoietic environment. However, this gradient was absent in B4-/-femurs, where we detected an increase of immature N-glycans and a concurrent decrease in complex N-glycan structures (p<0.05). Additionally, we observed aberrant O-glycosylation in B4-/- LT-HSCs, as determined using lectin arrays. The glycan composition in the absence of B4galt1-dependent glycosylation mirrors cancer-associated glycan patterns.
To further understand the role of B4galt1 in steady-state hematopoiesis, we next examined the bone marrow (BM) immunophenotypic composition of B4-/- mice. Flow cytometry analysis revealed a significant expansion of immunophenotypically defined long term (LT)-HSCs (p=0.0061) and multipotent progenitors (MPPs) (p<0.05) in B4-/-BM. Additionally, B4-/- LT-HSCs showed higher expression of the platelet marker CD41 (p=0.0171), suggesting the presence of an expanded megakaryocyte (MK) biased LT-HSCs population (LT-HSC CD41+ cells). This expansion occurred without pro-inflammatory cues, as determined through cytokine arrays.
To investigate if the global transcriptional landscape in B4-/- cells could explain the observed expansion phenotype, we conducted droplet-based single-cell RNA-seq. Transfer learning classification allowed us to identify an expansion of the transcriptional output associated with LT-HSC and MPP2 signatures in B4-/- cells (p<0.05). Further transcriptional analysis revealed an increased number of B4-/- cells expressing MKs specific markers (CD41, Pf4, GP9, Vwf, GP1ba), providing additional support for the expansion of B4-/- MK-biased LT-HSCs. Gene Set Enrichment Analysis (GSEA) of B4-/- LT-HSCs demonstrated enrichment in metabolism-associated pathways and cell cycle regulation (FDR<0.05). Conversely, critical differentiation processes at the stem cell level, such as cellular adhesion and lineage commitment, were downregulated (FDR<0.05).
To investigate the role of B4galt1 in HSC expansion, we transcriptionally classified LT-HSCs based on their cell cycle status (G1, G2M, and S). Analysis of LT-HSC CD41+ cell cycle distribution revealed an increased in S phase in B4-/- LT-HSC CD41+ cells. Additionally, B4-/- LT-HSC CD41+ cells exhibited enrichment in cell cycle regulation pathways, including DNA replication, DNA strand elongation, and G1 to S cell cycle control (FDR<0.05). Conversely, critical pathways associated with HSC homeostasis and quiescence were depleted in the absence of B4galt1 (FDR<0.05). GSEA analysis unveiled upregulation of Wnt and Myc pathways in B4-/- LT-HSC CD41+ cells. Immunofluorescence and immunoblot analysis demonstrated elevated total β-catenin levels in B4-/- LSK cells and enhanced nuclear translocation of non-phosphorylated Ser33/37/Thr41 β-catenin. To confirm the functional significance, we treated B4-/- LSK cells with the Wnt inhibitor XAV939 which normalized cell numbers to control levels and cause a reduction in the observed expansion at the stem and progenitor compartments. These findings suggest that B4galt1 is vital in regulating HSC expansion, likely through the Wnt/β-catenin signaling pathway.
Our data provide compelling evidence that B4galt1 regulates steady-state hematopoiesis, through its influence on glycosylation in the bone marrow niche, highlighting the critical role of the B4galt1-Wnt-β-catenin axis in regulating LT-HSC fitness and expansion.
Disclosures: No relevant conflicts of interest to declare.